title: Evaluation of a total core antigen assay for the diagnosis of hepatitis C virus infection in hemodialysis patients.
abstract: Hemodialysis patients are recognized as a group at high risk of infection with hepatitis C virus (HCV). Therefore, such a population should be screened routinely for the presence of HCV viremia. Since nucleic acid techniques remain expensive and largely unavailable in many laboratories in the developing world, the present study assesses the clinical usefulness of the HCV core antigen enzyme immunoassay for the diagnosis of HCV infection in dialysis patients. One hundred seventy-five dialysis patients were screened for the presence of anti-HCV antibodies and HCV RNA in the serum. One hundred twenty-eight serum samples were collected from the 76 patients who were anti-HCV antibody- and/or HCV RNA-positive. These were evaluated for total HCV core antigen. Of these samples, 55 had sufficient volume to be further tested to quantify HCV RNA by reverse transcription polymerase chain reaction (RT-PCR). Genotyping of the HCV strains showed that the majority belonged to genotype 1b (77%). The HCV core antigen assay showed a sensitivity and specificity of 84% and 89%, respectively. The use of core antigen assay has enabled the early detection of three patients who developed an acute hepatitis C infection during the period of study. A correlation study was undertaken between the quantitative values of viral load, expressed as pg/ml of HCV core antigen in serum, and viral RNA in UI/ml. A significant correlation was observed (Pearson's correlation coefficient: 0.552; P<0.001). In conclusion, detection of HCV core antigen in serum is an inexpensive, reliable, and highly specific assay that can be useful in most laboratory settings to diagnose HCV infection, and especially in laboratories where nucleic acid technologies are not yet available.
authors.affiliation: Laboratory of Molecular Immuno-Oncology, Faculty of Medicine, Monastir, Tunisia. nadia.bouzgarrou@lycos.com
authors.forename: N
authors.initials: N
authors.lastname: Bouzgarrou
authors.forename: I
authors.initials: I
authors.lastname: Fodha
authors.forename: S Ben
authors.initials: SB
authors.lastname: Othman
authors.forename: A
authors.initials: A
authors.lastname: Achour
authors.forename: F
authors.initials: F
authors.lastname: Grattard
authors.forename: A
authors.initials: A
authors.lastname: Trabelsi
authors.forename: B
authors.initials: B
authors.lastname: Pozzetto
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D016174:Hepacivirus / Q000302:isolation & purification*; D006526:Hepatitis C / Q000175:diagnosis* / Q000821:virology; D018937:Hepatitis C Antibodies / Q000097:blood*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012367:RNA, Viral / Q000097:blood; D006435:Renal Dialysis / Q000009:adverse effects*; D014758:Viral Core Proteins / Q000097:blood*; D019562:Viral Load; D014766:Viremia / Q000175:diagnosis / Q000821:virology
chemical_list: D018937:Hepatitis C Antibodies; D012367:RNA, Viral; D014758:Viral Core Proteins